Mechanism of action
Factor Xa inhibitor reversal agent.
Indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed because of life-threatening or uncontrolled bleeding.
Recombinant form of factor Xa, binding to factor Xa inhibitors, reversing their anticoagulant effect.
Indications and dose
Dose based on rivaroxaban or apixaban dose:
Use low dose described above
- Rivaroxaban dose ≤10 mg (any timing from last dose)
- Apixaban dose ≤5 mg (any timing from last dose)
- Rivaroxaban >10 mg or dose unknown (≥8 hr from last dose)
- Apixaban >5 mg or dose unknown (≥8 hr from last dose)
Use high dose described above
- Rivaroxaban >10 mg or dose unknown (<8 hr from last dose or unknown)
- Apixaban >5 mg or dose unknown (<8 hr from last dose or unknown)
Side-effects
Infusion-related reaction
Antibody development
Thrombosis
Pharmacokinetics
Routes: Intravenous
Onset: Rapid
Half-life of elimination: 1 hour
Medicinal forms
Powder as solution for infusion
1 vial = 200 mg, should be diluted e.g. in 20 ml of F/1/ (10 mg in 1 ml)
References
